Preclinical News and Research

RSS

U.S. FDA orders three TMJ implant manufacturers to conduct postmarket surveillance studies

Today the U.S. Food and Drug Administration ordered three manufacturers of temporomandibular joint implants to conduct postmarket surveillance studies to determine the length of time before the implants are removed or replaced due to pain or other reasons.

8 Feb 2011

Cleveland Clinic, JumpStart Ventures invest $500,000 in SironRX Therapeutics

JumpStart Ventures, the non-profit that invests in and partners with innovative, early-stage companies in Northeast Ohio, and Cleveland Clinic, announced a combined investment commitment of $500,000 in SironRX Therapeutics, Inc. The Cleveland-based company is developing a topical therapy to enhance healing of and decrease scar formation in wounds.

8 Feb 2011

Transition reports second quarter 2011 net income of $24.28M vs. $6.05M net loss for second quarter 2010

Transition Therapeutics Inc., a product-focused biopharmaceutical company developing therapeutics for disease indications with large markets, today announced its financial results for the quarter ended December 31, 2010.

8 Feb 2011

PharmaMar initiates PM060184 Phase I clinical trial in patients with solid tumors

PharmaMar SA has announced the commencement of a Phase I clinical trial with PM060184 for patients with solid tumors. PM060184 is a marine-derived, synthetically-produced compound which has shown strong in vitro and in vivo antitumor activity and a favorable safety profile in preclinical toxicology studies. PM060184 is PharmaMar's sixth compound in clinical development.

7 Feb 2011

USPTO issues key patent to ISTO's NuQu product for degenerative disc disease treatment

ISTO Technologies, Inc. announced today that the United States Patent and Trademark Office has granted the company a key patent covering the primary technology for ISTO's NuQu product.

7 Feb 2011

AMRI fourth quarter total revenue increases 12% to $48.6 million

AMRI today reported financial and operating results for the fourth quarter and full year ended December 31, 2010.

7 Feb 2011

EntreMed announces publication of ENMD-2076 Phase 1 results against solid tumors in AACR journal

EntreMed, Inc., today announced the publication of key papers on the clinical and preclinical development of ENMD-2076, an Aurora A/angiogenic kinase inhibitor. The clinical data were published in the December 3, 2010 on-line issue of the American Association for Cancer Research journal, Clinical Cancer Research, and are expected to appear soon in the print version of the publication.

4 Feb 2011

UofL receives $9.56 million NIH/NHLBI grant to study cardioprotective therapies

The National Heart, Lung and Blood Institute has awarded $9.56 million over five years to a University of Louisville Health Sciences Center research scientist to form a multi-center network examining cardioprotective therapies at the preclinical level.

4 Feb 2011

JDRF, Eli Lilly sign agreement to fund type 1 diabetes research for re-generative medicine

Eli Lilly and Company and the Juvenile Diabetes Research Foundation today announced that they have signed an agreement to fund early-stage research that could enable patients with type 1 diabetes to regenerate insulin-producing cells destroyed by the disease.

4 Feb 2011

Nitto Denko announces acquisition of Avecia Biotechnology

Japan's leading diversified materials manufacturer, Nitto Denko Corporation, today announced that it has acquired Avecia Biotechnology, Inc. through Nitto Americas, Inc., a wholly owned subsidiary in Teaneck, New Jersey.

3 Feb 2011

AVEO receives USAN, WHO generic name approval for ficlatuzumab

AVEO Pharmaceuticals, Inc. today announced that the United States Adopted Names (USAN) Council, in consultation with the World Health Organization (WHO) International Nonproprietary Names Expert Committee, has approved the use of the nonproprietary generic name "ficlatuzumab" (pronounced fye" kla tue' zue mab) for AV-299, a potent, functional anti-HGF/c-MET antibody internally discovered at AVEO.

3 Feb 2011

Concert and WRAIR enter CRADA to evaluate novel compound for seizure protection associated with TBI

Concert Pharmaceuticals, Inc. today announced that it has entered into a Cooperative Research and Development Agreement with the Walter Reed Army Institute of Research. The CRADA will allow the WRAIR to conduct preclinical testing on a novel compound derived from Concert's DCE Platform™ (deuterated chemical entity platform) for seizure protection associated with traumatic brain injury, a major public health concern.

3 Feb 2011

Positive results from Factor IX-CTP comparative study in hemophilic mice

PROLOR Biotech, today reported positive results from a comparative study of its biobetter longer-acting version of the hemophilia drug Factor IX in Factor IX-depleted hemophilic mice.

3 Feb 2011

Isis commences ISIS-FXIRx Phase 1 study for treatment of clotting disorders

Isis Pharmaceuticals, Inc. announced the initiation of a Phase 1 study of ISIS-FXIRx, an antisense drug designed to treat clotting disorders. ISIS-FXIRx inhibits the production of Factor XI, a clotting factor that is an important component of the coagulation pathway. Because of its role in the intrinsic coagulation pathway, inhibition of Factor XI could offer an effective approach for preventing the formation of blood clots with a lower risk of bleeding.

2 Feb 2011

Inovio publishes scientific paper detailing SynCon DNA vaccine preclinical study for prostate cancer

Inovio Pharmaceuticals, a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today the publication of a scientific paper in the journal Human Vaccines detailing potent immune responses in a preclinical study of Inovio's SynCon DNA vaccine for prostate cancer targeting two antigens.

2 Feb 2011

Targeted delivery combination crosses brain protecting barrier and homes in on tumors

A targeted delivery combination selectively crosses the tight barrier that protects the brain from the bloodstream to home in on and bind to brain tumors, a research team led by scientists from The University of Texas MD Anderson Cancer Center reported in the January issue of the Journal of Clinical Investigation.

2 Feb 2011

Harbor BioSciences announces publication of newly discovered anti-inflammatory steroids

Harbor BioSciences, a biopharmaceutical company developing novel therapeutics for the treatment of cancer, metabolic and inflammatory diseases, today announced publication of newly discovered anti-inflammatory steroids naturally present in humans.

2 Feb 2011

Boston-based Research 2.0 begins Viral Genetics coverage, publishes initial report

Boston-based Research 2.0 initiated coverage of Viral Genetics, Inc, and published their initial report today. The report is available on the company's website at www.viralgenetics.com/investors/press-releases/R20Report and is also distributed over the internet and through institutional platforms including FactSet, CapitalIQ, and TheMarkets.com.

2 Feb 2011

NIH awards multi-million dollar grant to form four-center cardiovascular research network

The National Heart, Lung and Blood Institute has awarded a multi-million dollar grant to Dr. Roberto Bolli of the University of Louisville to form a four-center network examining cardioprotective therapies at the preclinical level.

2 Feb 2011

Antares initiates dosing in VIBEX MTX clinical study for rheumatoid arthritis

Antares Pharma, Inc. today announced that the first patient has been dosed in a clinical study evaluating the VIBEX™ MTX product which is being developed for the treatment of rheumatoid arthritis. The clinical study will evaluate several dose strengths of VIBEX MTX delivered with a proprietary autoinjector versus conventional needle and syringe administration by a healthcare professional.

2 Feb 2011

Preclinical News and Research

U.S. FDA orders three TMJ implant manufacturers to conduct postmarket surveillance studies

Cleveland Clinic, JumpStart Ventures invest $500,000 in SironRX Therapeutics

Transition reports second quarter 2011 net income of $24.28M vs. $6.05M net loss for second quarter 2010

PharmaMar initiates PM060184 Phase I clinical trial in patients with solid tumors

USPTO issues key patent to ISTO's NuQu product for degenerative disc disease treatment

AMRI fourth quarter total revenue increases 12% to $48.6 million

EntreMed announces publication of ENMD-2076 Phase 1 results against solid tumors in AACR journal

UofL receives $9.56 million NIH/NHLBI grant to study cardioprotective therapies

JDRF, Eli Lilly sign agreement to fund type 1 diabetes research for re-generative medicine

Nitto Denko announces acquisition of Avecia Biotechnology

AVEO receives USAN, WHO generic name approval for ficlatuzumab

Concert and WRAIR enter CRADA to evaluate novel compound for seizure protection associated with TBI

Positive results from Factor IX-CTP comparative study in hemophilic mice

Isis commences ISIS-FXIRx Phase 1 study for treatment of clotting disorders

Inovio publishes scientific paper detailing SynCon DNA vaccine preclinical study for prostate cancer

Targeted delivery combination crosses brain protecting barrier and homes in on tumors

Harbor BioSciences announces publication of newly discovered anti-inflammatory steroids

Boston-based Research 2.0 begins Viral Genetics coverage, publishes initial report

NIH awards multi-million dollar grant to form four-center cardiovascular research network

Antares initiates dosing in VIBEX MTX clinical study for rheumatoid arthritis

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest Life Science News